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Long QT syndrome (LQTS) is a disorder of cardiac
repolarization characterized by a prolonged QT interval on
electrocardiogram (ECG). LQTS usually is referred to as a
monogenic disorder.1 QT interval in the population is
variable,2 which leads to many “borderline” cases and
makes deﬁnitive diagnosis difﬁcult.1 The utility of clinical
genetic screening in congenital LQTS has been demon-
strated,3 although issues remain with variants of unknown
signiﬁcance (VUS), false positives, and false negatives.4
The study and diagnosis of LQTS are additionally compli-
cated by a high degree of variable penetrance, making
genotyping a suboptimal predictor of clinical outcome and
complicating risk stratiﬁcation.5 Genetic testing companies
provide some guidance on the relevance of the mutations
identiﬁed. In the genetic screening performed in this study
through FAMILION, mutations are classiﬁed as class I
mutations, including deleterious and probable deleterious
mutants. Class II are possible deleterious mutations or
mutations of unknown signiﬁcance (VUS), and class III
are polymorphisms.
Most reported cases of congenital LQTS have a single
affected allele.3 Here we describe a family in which only
the proband presented with LQTS clinically, but genetic
testing revealed that all 5 family members studied carriedKEYWORDS Long QT syndrome; Mutation; Arrhythmia; Ion channel; Sudden
death
ABBREVIATIONS APD ¼ action potential duration; APD90 ¼ action
potential duration at 90% repolarization; ECG ¼ electrocardiogram;
HEK ¼ human embryonic kidney; LQT ¼ long QT; LQTS ¼ long QT
syndrome; LQT(2-3) ¼ long QT syndrome type (2-3); VUS ¼ variant of
unknown significance; WT ¼ wild type
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).at least 1 of 3 potential LQT mutations: 2 LQT2 mutations
in the potassium channel hERG (class I mutation: S654G;
class II mutation: A913V) and 1 LQT3 mutation in the
cardiac sodium channel SCN5A (class I mutation:
F1596I). Our objective was to use functional character-
ization and computational modeling to determine the
contribution to the LQT phenotype of 3 potential LQT
mutations identiﬁed in a single lineage. We hypothesized
this family presents a polygenic case of LQTS in which an
additive effect of the mutations leads to the LQT
phenotype.
Case report
Subjects completed a questionnaire that included general
health information, history of syncope, and medications.
Resting 12-lead ECGs were obtained. Symptom-limited
exercise tests were performed by the proband and his 2
sisters. QT interval was measured in multiple leads and
corrected for heart rate using the Bazett formula.
The proband in this study is a healthy 15-year-old boy
with no history of syncope diagnosed with LQTS after
presport ECG screening. He currently is symptom-free on
propranolol. Neither the proband nor any of his family
members had any history of syncope, disease, or chronic
medication use. Baseline resting ECG parameters and
genetic mutations are listed in Table 1 and shown in
Figure 3A. Multiple resting ECGs of the proband recorded
before his referral to this center showed QTc as high as 0.48
second. On presentation, QTc was 0.47 second. On exercise
test, QTc was 0.45 second lying and 0.46 second standing.
QTc shortened during exercise and gradually prolonged back
to 0.47 second at the end of recovery. T waves showed slight
notching.
Sister 1 (SCN5A-F1596I) had normal QTc at baseline
(0.41 second) and with both lying (0.40 second) and standing
(0.44 second). There was no signiﬁcant prolongation of QTc
during exercise or recovery. T-wave morphology was
normal. Sister 2 (KCNH2-A013V) had normal QTc at
baseline (0.42 second). With lying and standing, QTcpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.02.011
KEY TEACHING POINTS
 Although all mutations identiﬁed in this family
were classiﬁed as likely long QT (LQT) mutations,
functional characterization and in silico modeling
suggest that this family actually presents with a
case of polygenic LQTS in which a variant with
minor biophysical defects combined with a more
severe mutation actually produces additive effects
leading to a prolonged QTc.
 This study highlights that functional
characterization is extremely pertinent to correlate
the role of the mutations to the clinical phenotype
and should remain an important part of genetic
mutation classiﬁcations.
 Our results suggest that clinicians should be
cautious when using solely the genetic screening
results and classiﬁcation for decision-making.
Heart Rhythm Case Reports, Vol 1, No 4, July 2015202increased from 0.42 to 0.46 second. QTc increased to 0.48
second during early exercise and reached 0.47 second during
recovery. T waves showed notching. The T waves of the
mother and father showed normal morphology.
Genetic testing was performed using the FAMILION test
(Transgenomic Inc, New Haven, CT). The proband was
tested for mutations in the genes implicated in LQT1-13.
Family members were tested for the known class I and II
mutations reported in the proband. Genetic testing revealed
that every member carries at least 1 class I or class II
mutation, although only the proband displays a prolonged
QTc (Figure 3A). The KCNH2/hERG-S654G mutation is
classiﬁed by the FAMILION genetic testing as class I.
hERG-A913V is scored as class II by FAMILION. Both
mutations have been potentially linked to arrhythmia,
although they have not been functionally characterized.6,7
SCN5A-F1596I was scored as class I by FAMILION. It has
been potentially linked with arrhythmia but not shown to be
pathogenic.8 In order to assess which mutation(s) is at the
source of the LQT phenotype and identify which family
members may be at risk, functional characterization of the
mutations was performed (see Online Supplementary
Material for detailed methods of the functional character-
ization and in silico modeling).Table 1 Clinical features of the family studied
Age (years) Sex Mutations
Proband 15 M SCN5A-F1596I
hERG-S654G
hERG-A913V
Mother 39 F SCN5A-F1596I
hERG-S654G
Father 40 M hERG-A913V
Sister 1 13 F SCN5A-F1596I
Sister 2 7 F hERG-A913VFunctional analysis of SCN5A-F1596I
The SCN5A-F1596I mutation was expressed and character-
ized in HEK293 cells (Table 2). Peak current density was
equal to wild type (WT; Figure 1A). Steady-state inactiva-
tion shifted slightly þ4.9 mV (Figure 1B). Activation V0.5
and k were unchanged (Figure 1B). The time constant of
recovery from inactivation was faster than WT (Figure 1C).
Persistent current of SCN5A-F1596I relative to peak current
(0.9%) was increased compared to WT (0.5%; Figures 1D
and 1E). These changes, although modest, are the signature
of an LQT3 mutation.
Functional analysis of hERG mutations
hERG constructs were characterized in HEK293 cells
(Figure 2). The hERG-A913V mutation resulted in a 37%
decrease in tail current (Figures 2B and 2E). hERG-S654G
showed a distinct loss of function, with tail current density
decreased approximately 70% (Figures 2C and 2F). Other
biophysical properties were not modiﬁed for either mutant.
Coexpression of both hERG-S654G and hERG-A913V
resulted in a decrease in currents consistent with an average
effect of both mutations (Figures 2D and 2G).
Simulated effect of mutations on action potential
duration
To further explore which mutation(s) was needed to explain the
presence of LQT in the proband, we simulated the effects of the
mutations on the human ventricular action potential in silico.9
SCN5A-F1596I was deﬁned as an 80% increase in late current,
aþ5-mV shift in steady-state inactivation, and a 40% change in
the time constant of recovery of inactivation. KCNH2-A913V
was deﬁned as a 37% decrease in conductance for IKr.KCNH2-
S654G was deﬁned as a 73% decrease of conductance in IKr.
All changes were adjusted to account for heterozygosity. At
baseline, the model gives an action potential duration at 90%
repolarization (APD90) of approximately 265 ms. The sister’s
SCN5A-F1596I genotype gives a slight prolongation of APD90
byo10 ms. The father/sister hERG-A913V gives an approx-
imately 30-ms prolongation of APD90. The mother’s genotype,
both SCN5A-F1596I and KCNH2-S654G, increased APD90 by
approximately 75 ms. Finally, simulating the proband gave the
longest APD90 at approximately 420 ms, increased by approx-
imately 160 ms (Figure 3B).
To assess what combination of mutations is the key factor
in the LQT phenotype seen only in the proband, we alsoHeart rate (bpm) QT (seconds) QTc (seconds)
93 0.38 0.47
71 0.39 0.43
61 0.29 0.39
83 0.35 0.41
83 0.36 0.42
Table 2 SCN5A biophysical properties
n
Steady-state
inactivation V0.5 (mV)
Steady-state
inactivation slope factor k
Activation
V0.5 (mV)
Activation slope
factor k
Recovery from
inactivation τ (ms)
WT 7 –81.6  0.9 5.9  0.1 –37.9  3.1 5.1  0.5 5.1  0.2
F1596I 11 –86.5  1.1* 6.2  0.2 –37.8  6.4 4.2  0.5 3.7  0.4*
*P o.05 compared to wild type (WT).
203Hoshi et al Polygenic Case of Long QT Syndromemodeled the isolated effect of hERG-S654G and then of both
hERG mutations combined (Figure 3C). This combination
leads to a prolongation of 145 ms, about 15 ms short of the
proband’s predicted APD, demonstrating that his LQT
phenotype is due mainly to the dual hERG mutant genotype.
Because no other family members presented with this
unlucky combination, our results suggest this combination
explains the LQTS seen in the proband, who therefore
presents with a polygenic case of LQTS.Discussion
The decrease in IKr seen with hERG-S654G is consistent
with an LQT2 mutation.2,10 It had a signiﬁcant impact on
simulated APD (Figure 3C). Based on these data, we concur
with the classiﬁcation of this mutation as a class I and believe
that the presence of this mutation alone could be sufﬁcient
for LQTS. However, no family members had that genotype,
and even the mother who carries this mutation along with the
SCN5A mutant does not have LQT.
The hERG-A913V mutation produced minor deﬁcits
(73% that of WT at the homozygous state; Figure 2E). This
mutation was classiﬁed as a VUS (class II) by FAMILION.No
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Figure 1 Biophysical properties of SCN5A-F1596I.A: Current–voltage relations
and inactivation C: Recovery from inactivation for F1596I. D: Representative o
channels. The persistent current at 500 ms is shown in the inset. E: Summary datOur biophysical characterization shows very minor changes;
carrying hERG-A913V along with a WT allele would bring
the net current to 85% of WT. It seems this mutation alone is
insufﬁcient to lead to an LQT phenotype, experimentally and
phenotypically. However, this raises the important possibil-
ity that the presence of multiple VUS with minor biophysical
defects could be additive and could combine to produce a
prolongation of APD, leading to an LQT phenotype.
An important additive effect is notable upon comparison
of the hERG-A913VþhERG-WT condition (father/sister)
with the hERG-A913VþhERG-S654G proband. In the
former, the presence of hERG-A913V contributes to an
approximately 30-ms prolongation of APD. In the latter,
hERG-A913V compounds an already present reduction in
IKr (hERG-S654G) and prolongs APD by approximately 60
ms (Figures 3B and 3C), showing a greater than additive
effect of dual mutation status on APD.Implications for the family
Overall, the data suggest that, after the proband, the mother
may be at highest risk for developing arrhythmias. There is
good agreement between clinical QTc and predicted APD%
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hip of wild type (WT; n¼ 7) and F1596I (n¼ 11). B: Steady-state activation
verlaid traces of a persistent current protocol for WT and SCN5A-F1596I
a of persistent current experiments.
A C
B
Figure 3 In silico effect of mutations on action potential duration (APD). A: Family tree of affected long QT (LQT) lineage. QTc at screening is indicated in
seconds. Shading denotes the long QT syndrome (LQTS)–diagnosed proband carrying all 3 mutations. B: Predicted effect of family mutation status on APD. C:
Isolating the effect of hERG-S654G and both hERG mutations from the proband’s simulated action potential shows all but approximately 15 ms of the
prolongation is attributable to hERG-S654G and hERG-A913V together.
A B C D
E F G
Figure 2 Characterization of hERG-A913V and hERG-S654G. A–D: Representative current traces E: Plot of tail current from A913V (n ¼ 12) vs wild type
(WT; n ¼ 12). Po.05 for voltages420 mV. F: Plot of tail current from S654G (n ¼ 9) vs WT (n ¼ 11). Po.05 for voltages420 mV. G: Plot of tail current
from hERG-S654GþhERG-A913V (n ¼ 11) vs WT (n ¼ 12). P o.05 for voltages40 mV.
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205Hoshi et al Polygenic Case of Long QT Syndrome(Figure 3). However, a strict comparison between QTc and
APD is imperfect, as highlighted by the father and a
daughter, both of whom carry hERG-A913V but have
differing QTc (0.39 and 0.42 second, respectively). Con-
founding factors include gender, variable penetrance, heart
rate, and other unexplored disease-modifying genes. Indeed,
although of doubtless use, in vitro, in silico, or genetic
studies of LQT mutations may remain secondary in utility to
the individual patient’s phenotype in risk assessment.11
It seems that in the absence of carrying all 3 mutations (as
in the proband), minor deﬁcits caused by SCN5A-F1596I and
hERG-A913V in the other family members are insufﬁcient to
induce an LQT phenotype. This may be related to repolari-
zation reserve.12 The cell maintains sufﬁcient repolarizing
capacity to overcome any induced deﬁcits. Indeed, stepwise
decreases of IKr lead to a disproportionate prolongation of
APD for dual hERG mutation status (Figures 3B and 3C).
Additionally, the contribution of unexplored polymorphisms
carried by unaffected family members cannot be discounted.
Ultimately, from our data, it seems possible that the unlucky
proband’s compound heterozygosity at hERG combined
with a mutation in SCN5A is sufﬁcient to result in
clinical LQTS.
Implications for the clinician
Despite the utility of clinical genetic screening in congenital
LQTS,7 distinguishing benign variants from pathologic
mutations is complicated by both false positives and
negatives, and incomplete penetrance.4 Genotyping becomes
a suboptimal predictor of clinical outcome and therefore is
mainly used by clinicians to conﬁrm the genotype of the
disease in affected individuals or to rule out nonaffected
nonmutation carriers from further follow-up. Issues remain
for a third group: apparently nonaffected mutation carriers.
This study represents an additional complexity in that the
family presented with 3 separate potential LQTS mutations
and only 1 affected individual. We used functional character-
ization and in silico modeling to explore the role of these 3
mutations and show that this is likely a case of polygenic
LQTS in which the presence of a VUS with modest
biophysical defects becomes important only in the presence
of another disease-causing mutation.
Crucially, our experiments with SCN5A-F1596I show it
seems insufﬁcient to cause disease.13 This, along with the
unaffected status of the carrier daughter (Figure 3A), makes
it likely that SCN5A-F1596I alone does not cause LQTS
despite it being classiﬁed as a class I mutation. This
demonstrates the importance of functional characterization
and highlights that the algorithms used by genetic testing
companies to classify mutations are not necessarily accurate.
Although all mutations identiﬁed in this family were
classiﬁed as likely LQT mutations (1 was VUS), functionalcharacterization and in silico modeling suggest that this
family actually presents with a case of polygenic LQTS in
which a VUS with minor biophysical defects combined with
a more severe mutation actually produces additive effects
leading to a prolonged QTc. Importantly, the functional
characterization and in silico modeling support the clinical
phenotype of this family in which only 1 individual is
affected. This study highlights that functional character-
ization is extremely pertinent to correlate the role of the
mutations to the clinical phenotype and should remain an
important part of genetic mutation classiﬁcations. Our results
also suggest that clinicians should be cautious when using
solely the genetic screening results and classiﬁcation for
decision-making.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrcr.2015.
02.011.
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